PAVmed (PAVM) Fundamentals 2026 — Revenue Analysis | SniperIQ
PAVmed (PAVM) is a US-listed Healthcare company in Medical - Devices with a market capitalization of
PAVmed (PAVM) has a market capitalization of approximately
PAVmed's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
PAVmed runs a net profit margin of -21914.1%, a gross margin of -271.8%, and an operating margin of -28702.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
PAVmed reported revenue of $71,000 for fiscal year 2025, with net income of $401,000 and earnings per share (EPS) of -5.63. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
PAVmed does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
PAVmed carries a debt-to-equity ratio of 0.43x and a current ratio of 2.02x, with a market beta of 0.55. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PAVmed (PAVM) the key facts are: market cap
Get PAVmed's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.